Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Fetuin-A (AHSG) Human, Goat Polyclonal Antibody

  • Regulatory status:RUO
  • Type:Polyclonal Antibody
  • Other names:Alpha-2-HS-glycoprotein, Ba-alpha-2-glycoprotein, Alpha-2-Z-globulin, Fetuin A, AHSG, FETUA, PRO2743
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RD184036100 0.1 mg
PubMed Product Details
Technical Data

Type

Polyclonal Antibody

Applications

Western blotting, ELISA, Immunoturbidimetry, Immunohistochemistry

Antibodies Applications

Source of Antigen

Human serum

Hosts

Goat

Preparation

The antibody was raised in goat by immunization with the Human Fetuin.

Species Reactivity

Human. Not yet tested in other species.

Purification Method

Immunoaffinity chromatography on a column with immobilized purified Human Fetuin.

Antibody Content

0.1 mg (determined by BCA method, BSA was used as a standard)

Formulation

The antibody is lyophilized in 0.05 M phosphate buffer, 0.1 M NaCl, pH 7.2. AZIDE FREE.

Reconstitution

Add 0.1 ml of deionized water and let the lyophilized pellet dissolve completely. Slight turbidity may occur after reconstitution, which does not affect activity of the antibody. In this case clarify the solution by centrifugation.

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

The lyophilized antibody remains stable and fully active until the expiry date when stored at –20°C. Aliquot the product after reconstitution to avoid repeated freezing/thawing cycles and store frozen at –80°C. Reconstituted antibody can be stored at 4°C for a limited period of time; it does not show decline in activity after one week at 4°C.

Quality Control Test

Indirect ELISA – to determine titer of the antibody SDS PAGE – to determine purity of the antibody

Note

This product is for research use only.

Summary

Research topic

Bone and cartilage metabolism, Cardiovascular disease, Renal disease

Summary

Fetuin-A (AHSG), a 59 kDa glycoprotein, consisting of two cystatin-like domains and a smaller unrelated domain, is predominantly synthesized in liver. It is secreted into the blood stream and deposited as a noncollagenous protein in mineralized bones and teeth. Fetuin-A occurs in high serum concentrations during foetal life, whereas its level declines following infection, inflamatory and malignancy. Fetuin-A acts as an important circulating inhibitor of ectopic calcification, frequent complication of many degenerative diseases. Low serum level of Fetuin-A is associated with vascular and valvular calcification, atherosclerosis, malnutrition and higher cardiovascular mortality in chronic renal failure, liver cancer and liver cirrhosis patients on long-term dialysis. AHSG protein represents a natural inhibitor of tyrosinase kinase activity of the insulin receptor. It may play a significant role in regulating postprandial glucose disposal, insulin sensitivity, weight gain, and fat accumulation. The serum and bone-resident Fetuin-A binds to transforming growth factor-β and blocks TGF-β binding to cell surface receptors.

Product References (5)

References

  • Fisher E, Stefan N, Saar K, Drogan D, Schulze MB, Fritsche A, Joost HG, HäringHU, Hubner N, Boeing H, Weikert C. Association of AHSG gene polymorphisms withfetuin-A plasma levels and cardiovascular diseases in the EPIC-Potsdam study.Circ Cardiovasc Genet. 2009 Dec;2(6):607-13. doi:10.1161/CIRCGENETICS.109.870410. Epub 2009 Sep 5. PubMed PMID: 20031641. See more on PubMed
  • Kröger J, Meidtner K, Stefan N, Guevara M, Kerrison ND, Ardanaz E, Aune D,Boeing H, Dorronsoro M, Dow C, Fagherazzi G, Franks PW, Freisling H, Gunter MJ,Huerta JM, Kaaks R, Key TJ, Khaw KT, Krogh V, Kühn T, Mancini FR, Mattiello A,Nilsson PM, Olsen A, Overvad K, Palli D, Quirós JR, Rolandsson O, Sacerdote C,Sala N, Salamanca-Fernández E, Sluijs I, Spijkerman AMW, Tjonneland A, TsilidisKK, Tumino R, van der Schouw YT, Forouhi NG, Sharp SJ, Langenberg C, Riboli E,Schulze MB, Wareham NJ. Circulating Fetuin-A and Risk of Type 2 Diabetes: AMendelian Randomization Analysis. Diabetes. 2018 Jun;67(6):1200-1205. doi:10.2337/db17-1268. Epub 2018 Mar 9. PubMed PMID: 29523632; PubMed Central PMCID: PMC6278908. See more on PubMed
  • Roos M, Lutz J, Salmhofer H, Luppa P, Knauss A, Braun S, Martinof S, SchömigA, Heemann U, Kastrati A, Hausleiter J. Relation between plasma fibroblast growthfactor-23, serum fetuin-A levels and coronary artery calcification evaluated bymultislice computed tomography in patients with normal kidney function. ClinEndocrinol (Oxf). 2008 Apr;68(4):660-5. Epub 2007 Oct 29. PubMed PMID: 17970775. See more on PubMed
  • Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Häring HU, Schulze MB.Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes. 2008Oct;57(10):2762-7. doi: 10.2337/db08-0538. Epub 2008 Jul 15. PubMed PMID:18633113; PubMed Central PMCID: PMC2551687. See more on PubMed
  • Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, Häring HU,Boeing H, Fritsche A. Plasma fetuin-a levels and the risk of myocardialinfarction and ischemic stroke. Circulation. 2008 Dec 9;118(24):2555-62. doi:10.1161/CIRCULATIONAHA.108.814418. Epub 2008 Nov 24. PubMed PMID: 19029462. See more on PubMed
Summary References (18)

References to Fetuin-A

  • Arnaud P, Kalabay L. Alpha2-HS glycoprotein: a protein in search of a function. Diabetes Metab Res Rev. 2002 Jul-Aug; 18(4): 311-4. Review.
  • Denecke B, Graber S, Schafer C, Heiss A, Woltje M, Jahnen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J. 2003 Nov 15; 376(Pt 1): 135-45.
  • Floege J, Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant. 2004 Aug;19 Suppl 5:V59-66
  • Geroldi D, Minoretti P, Bianchi M, Di Vito C, Reino M, Bertona M, Emanuele E. Genetic association of alpha2-Heremans-Schmid glycoprotein polymorphism with late-onset Alzheimer's disease in Italians. Neurosci Lett. 2005 Oct 7;386 (3):176-8
  • Heiss A, DuChesne A, Denecke B, Grotzinger J, Yamamoto K, Renne T, Jahnen-Dechent W. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem. 2003 Apr 11;278 (15):13333-41
  • Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. 2006 Apr 11;113 (14):1760-7
  • Jersmann HP, Dransfield I, Hart SP. Fetuin/alpha2-HS glycoprotein enhances phagocytosis of apoptotic cells and macropinocytosis by human macrophages. Clin Sci (Lond). 2003 Sep; 105(3): 273-8.
  • Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003 Mar 8; 361(9360): 827-33.
  • Kundranda MN, Henderson M, Carter KJ, Gorden L, Binhazim A, Ray S, Baptiste T, Shokrani M, Leite-Browning ML, Jahnen-Dechent W, Matrisian LM, Ochieng J. The serum glycoprotein fetuin-A promotes Lewis lung carcinoma tumorigenesis via adhesive-dependent and adhesive-independent mechanisms. Cancer Res. 2005 Jan 15;65 (2):499-506
  • Kwak JY, Ma TZ, Yoo MJ, Choi BH, Kim HG, Kim SR, Yim CY, Kwak YG. The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp Hematol. 2004 Sep;32 (9):836-42
  • Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest. 1979 Oct;64 (4):1118-29
  • Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, Gupta A, Norris K, Ketteler M, Adler S. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 2005 Mar;67 (3):1070-7
  • Osawa M, Tian W, Horiuchi H, Kaneko M, Umetsu K. Association of alpha2-HS glycoprotein (AHSG, fetuin-A) polymorphism with AHSG and phosphate serum levels. Hum Genet. 2005 Feb;116 (3):146-51
  • Osawa M, Umetsu K, Sato M, Ohki T, Yukawa N, Suzuki T, Takeichi S. Structure of the gene encoding human alpha 2-HS glycoprotein (AHSG). Gene. 1997 Sep 1;196 (1-2):121-5
  • Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res. 2003 Oct 21;118 (1-2):140-6
  • Reynolds JL, Skepper JN, McNair R, Kasama T, Gupta K, Weissberg PL, Jahnen-Dechent W, Shanahan CM. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol. 2005 Oct;16 (10):2920-30
  • Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003 Aug; 112(3): 357-66.
  • Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W. Th
Related Products Docs